Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IONIS-DGAT2Rx in T2DM with Hepatic Steatosis
NCT03334214Phase 2Completed
- Sponsor
- Ionis Pharmaceuticals
- Start
- Nov 2017
- Primary completion
- Nov 2018
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 4
01
Overview
A Phase 2 trial of IONIS-DGAT2Rx in non-alcoholic fatty liver disease (NAFLD), type 2 diabetes mellitus (T2DM), sponsored by Ionis Pharmaceuticals. Started Nov 2017; status: completed.
02
Drugs
IONIS-DGAT2Rx
03
Conditions
non-alcoholic fatty liver disease (NAFLD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT03334214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03334214.